Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 121   

Articles published

JNJ 103.73 +0.78 (0.76%)
price chart
Johnson & Johnson to Seek Buyer for Cordis Medical-Device Unit
The sales process for the business, called Cordis, is at an early stage, the people said. The business, which could fetch between $1.5 billion and $2 billion, is expected to attract interest from private-equity firms and other health-care companies ...
Johnson & Johnson to seek buyer for medical device maker unit: WSJ  Reuters
Johnson & Johnson Said Exploring Sale of Cordis Devices Business  Bloomberg
Related articles »  
Will Johnson & Johnson (JNJ) Stock Benefit From Cordis Unit Sale?
NEW YORK (TheStreet) -- Johnson & Johnson (JNJ) will seek a buyer for its Cordis unit, a business that makes medical devices including stents and catheters, sources say, in the latest move by the health care company to reduce its wide ranging portfolio ...
Johnson & Johnson Praised for Taking Uterine Surgery Tools Off Market
Johnson & Johnson, which has come under withering criticism for its response to problems with some of its medical devices, won cautious praise from critics on Thursday for its decision to withdraw three products used in uterine surgery because of a ...
Johnson & Johnson Pulls Controversial Device That May Spread Cancer  Huffington Post
Johnson & Johnson recalls hysterectomy power morcellator that may spread ...  Tech Times
Related articles »  
Johnson & Johnson Plans To Divest Its Cordis Business
Johnson & Johnson Plans To Divest Its Cordis Business. 52. SHARES. Johnson & Johnson Plans To Divest Its Cordis Business.
Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than ...
It isn't surprising to see that the European Commission has given Bristol-Myers Squibb (NYSE: BMY ) the go-ahead for daclatasvir, Bristol's promising new hepatitis C treatment.
Related articles »  
Johnson & Johnson recalls some jaw implants after reports of injury
Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.
Why Johnson & Johnson (JNJ) Stock Is Declining Today
Related articles »  
3 Reasons Johnson & Johnson Stock Could Rise
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ ) might be a $280-plus billion dollar company, but it's certainly not growing like one as evidenced by the company's robust growth reported in the second quarter.
Related articles »  
Johnson & Johnson Becomes #14 Most Shorted Dow Stock, Replacing Procter ...
The most recent short interest data has been released by the NASDAQ for the 08/15/2014 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by ...
Related articles »  
5 Things Johnson & Johnson's Management Wants You to Know
A month ago today healthcare giant Johnson & Johnson (NYSE: JNJ ) reported what looked on the surface to be another stellar quarter of growth.
Robert Wood Johnson's New Industry Made Surgery Safer  Investor's Business Daily
Related articles »  
Morgan Stanley Sees More Focused Device Strategy Continue For Johnson ...
In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ). In the report, Morgan Stanley noted, �The Wall Street Journal is reporting that J&J is seeking a buyer for Cordis, ...